Viemed Healthcare
VMD
81 hedge funds and large institutions have $151M invested in Viemed Healthcare in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 3 closing their positions.
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
37% more capital invested
Capital invested by funds: $110M → $151M (+$41.1M)
25% more funds holding
Funds holding: 65 → 81 (+16)
5.93% more ownership
Funds ownership: 47.88% → 53.8% (+5.9%)
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
Top Buyers
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$844K |
| 2 |
CSC
Cove Street Capital
El Segundo,
California
|
-$708K |
| 3 |
Renaissance Technologies
New York
|
-$605K |
| 4 |
E
Ergoteles
New York
|
-$503K |
| 5 |
Millennium Management
New York
|
-$464K |
VMD Hedge Fund Activity: Q4 2022 in Review
81 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Viemed Healthcare (VMD) for Q4 2022, worth a combined $151M — up 37% from $110M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VMD positions and 3 closed out — a net gain of 16 holders — while 19 added to existing stakes and 21 trimmed.
The largest buyer was Forager Capital Management, opening a new position worth an estimated $11.9M. The largest seller was Marshall Wace, exiting entirely with an estimated $844K sold.
- 81 institutional investors held Viemed Healthcare (VMD) as of Q4 2022, up from 65 in Q3 2022.
- Funds reported $151M of Viemed Healthcare stock for Q4 2022, up 37% quarter-over-quarter.
- 19 funds opened new Viemed Healthcare positions in Q4 2022 and 3 closed out, a net change of +16 holders.
- The largest Viemed Healthcare buyer in Q4 2022 was Forager Capital Management, an estimated $11.9M added.
- The largest Viemed Healthcare seller in Q4 2022 was Marshall Wace, an estimated $844K sold.
Based on aggregated 13F filings for Q4 2022.